Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 6

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 6
---
  

  maintain, protect and expand our intellectual property portfolio;  

  attract and retain skilled personnel;  

  create additional infrastructure to support our operations as a publicly quoted company and our product development and planned future commercialization efforts;  

  add an internal sales force; and  

  experience any delays or encounter issues with any of the above.  

Until our drug candidates
become commercially available, we will need to obtain additional funding in connection with the further development of our drug candidates.
Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance
and investor sentiment. As such, additional financing may not be available to us when needed, on acceptable terms, or at all. If we are
unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development
programs or any future commercialization efforts or obtain funds by entering agreements on unattractive terms.

Furthermore, any additional
equity fundraising in the capital markets may be dilutive for shareholders and any debt-based funding may bind us to restrictive covenants
and curb our operating activities and ability to pay potential future dividends even when profitable. We cannot guarantee that future
financing will be available in sufficient amounts or on acceptable terms, if at all. If we are unable to raise additional capital in sufficient
amounts or on acceptable terms, we will be prevented from pursuing research and development efforts. This could harm our business, operating
results and financial condition and cause the price of our ADSs to fall.

If we are unable to secure
sufficient capital to fund our operations, then we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to third parties to develop and market drug candidates that we would otherwise prefer to develop
and market ourselves. For example, strategic collaborations could require us to share commercial rights to our drug candidates with third
parties in ways that we do not intend currently or on terms that may not be favorable to us. Moreover, we could also be required to relinquish
valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may
not be favorable to us.

We may find it difficult to enroll patients in our clinical trials,
and patients could discontinue their participation in clinical trials, which could delay or prevent clinical trials and make those trials
more expensive to undertake.

Identifying and qualifying
patients to participate in current and